Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
As a leading provider of Chimeric Antigen Receptor (CAR) field, Creative Biolabs provides CellRapeutics™ VHH-based CAR construction service according to diverse needs in different scientific projects. VHH-based chimeric receptor is considered as the fourth generation of CAR, which has been successfully studied in cancer targeting researches.
A figure adapted from Meyer et al., 2014.
De Meyer T, Muyldermans S, Depicker A. VHH-based products as research and diagnostic tools. Trends Biotechnol. 2014 May;32(5):263-70.
A figure from In Vivo Cellular and Molecular Imaging Brussels (ICMI Brussels), Vrije Universiteit Brussel.
VHH (Nb) is the variable domain of heavy-chain antibodies (also as known as VHH). It is the smallest antibody fragment with complete function. Generally, it only has half the molecular weight of a single-chain variable fragment (scFv), which is able to trigger an immune response. The advantage of Nb is its lower immunogenicity and better pharmacokinetics as a result of its small size and high affinity to target antigen. VHH-based conjugates such as Nb-enzyme, Nb-exotoxin or Nb-T cell are becoming potential strategies applied in tumor targeting treatment.
Technically, we can generate an Nb gene library derived from lymphocytes of camels, and then screen this Nb library with tumor associated antigens. After isolating the specific Nb, we will construct CAR-T cells with this specific-Nb (VHH-based CAR) instead of a scFv, which is different from classical CAR. Furthermore, we can also generate humanized camelid Nb according to your specific needs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
